StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for GRCE yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $2.13 | $2.17 | +1.88% | 0.4M |
| 05-19 | $2.14 | $2.15 | +0.47% | 0.3M |
| 05-20 | $2.11 | $2.18 | +3.32% | 0.3M |
| 05-21 | $2.15 | $2.24 | +4.19% | 0.2M |
| 05-22 | $2.25 | $2.20 | -2.22% | 0.3M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2022 2022-03-31 | Q4 2021 2021-12-31 | Annual 2021 2021-03-31 | Q4 2020 2020-12-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $196.00K | $81.00K |
Operating Income | $-15.59M | $-11.19M | $-16.42M | $-14.12M |
Net Income | $-9.82M | $-5.92M | $-19.68M | $-14.03M |
EPS (Diluted) | $-0.27 | $-0.23 | Not available | Not available |
Total Assets | $128.62M | $114.23M | $62.46M | $30.30M |
Total Liabilities | $20.35M | $3.17M | $6.80M | $4.59M |
Cash & Equivalents | $30.34M | $33.01M | $50.94M | $26.55M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 44.29M | 25.79M | Not available | Not available |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.